Universal Health Services Faces Challenges Despite Recent Revenue Growth
Universal Health Services, Inc. (UHS), headquartered in King of Prussia, Pennsylvania, is a major player in the healthcare sector. With a market capitalization of nearly $12 billion, the company oversees a diverse array of facilities, including acute care hospitals and behavioral health centers in both the United States and the United Kingdom.
As a “large-cap” stock, UHS is categorized alongside companies valued at $10 billion or more. It ranks as one of the largest for-profit healthcare systems in the U.S., boasting a network that includes general acute care hospitals and behavioral health facilities. Significant revenue growth has recently stemmed from its behavioral health division.
Despite some achievements, UHS’s stock has seen a decline of 22.8% from its 52-week peak of $243.25 on September 24. On a more positive note, the stock has rebounded, climbing 4.1% over the past three months, in contrast to the Dow Jones Industrial Average’s ($DOWI) 2.3% decrease during the same period.
Over the past year, UHS reported a modest gain of 3%, although this is below the $DOWI’s 5.5% return. In the preceding six months, the stock fell by 18.3%, again trailing behind the $DOWI’s slight decline.
Recently, however, the stock showed signs of recovery, breaking above its 50-day moving average after being below the 200-day moving average since early December, which could indicate a potential rebound.
Concerns regarding changes in Medicaid reimbursement rates and increasing expenses have contributed to UHS’s underperformance in the market over the last year, impacting investor confidence.
On February 26, UHS announced its fourth-quarter earnings, prompting a 3.3% rise in its share price in the following trading session. The company reported net revenues of $4.1 billion, an 11.1% increase from the same quarter the previous year, surpassing market estimates. Adjusted net income was reported at $4.92 per share, exceeding Wall Street’s forecasts. For 2025, UHS anticipates consolidated net revenues between $17.02 billion and $17.36 billion, with diluted earnings per share projected to range from $18.45 to $19.95.
Nonetheless, UHS has been outperformed by its main competitor, HCA Healthcare, Inc. (HCA), which has seen a 3.6% gain over the past year, despite experiencing a 14.3% drop over the last six months.
Although UHS’s stock has faced headwinds recently, analysts remain cautiously optimistic about its future. The stock holds a consensus rating of “Moderate Buy” from 18 analysts, with a mean price target of $231.53, suggesting a potential upside of 23.2% from its current price.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy
here.
More news from Barchart
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
